HIF-EPO-Iron
| Zeile 12: | Zeile 12: | ||
'''Iron chelators''' | '''Iron chelators''' | ||
{{tp|p=32418885|t=2020. Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?|pdf=|usr=009}} | {{tp|p=32418885|t=2020. Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?|pdf=|usr=009}} | ||
| + | {{tp|p=32607779|t=2020. Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome?|pdf=|usr=011}} | ||
Version vom 8. Juli 2020, 10:33 Uhr
HIF1
32464493 2020. Hypoxia inducible factor-1 protects against COVID-19: A hypothesis.
Erythropoietin
32270515 2020. Does recombinant human Erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?
32479920 2020. Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19.
32534130 2020. EPO in Patients With COVID-19: More Than an Erythropoietic Hormone.
32522574 2020. Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?
32546125 2020. Erythropoietin as candidate for supportive treatment of severe COVID-19.
Iron chelators
32418885 2020. Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?
32607779 2020. Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome?
